NEW YORK,, Oct. 9, 2012
NEW YORK, Oct. 9, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
TechNavio's analysts forecast the Global Hepatitis Drugs market to grow at a CAGR of 12.42 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increase in demand for hepatitis drugs in developing countries. The Global Hepatitis Drugs market has also been witnessing an increase in the number of mergers and acquisitions. However, the shortage of hepatitis drugs to meet market demand could pose a challenge to the growth of this market.
TechNavio's report, the Global Hepatitis Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hepatitis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Bristol-Myers Squibb Co., Gilead Sciences Inc., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Merck & Co. Inc.
Other vendors mentioned in the report: :
Dainippon Sumitomo Pharma Co. Ltd., Vertex Pharmaceuticals Inc., Novartis AG, Abbott Laboratories, Achillion Pharmaceuticals Inc., Boehringer Ingelheim GmbH, and Idenix Pharmaceuticals Inc.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of analyst time when you purchase this report. Details provided within the report.
01. Executive Summary
03. Market Coverage
04. Market Landscape
04.1 Overall Global Hepatitis Drugs Market
04.2 Key Market Segmentation
04.3 Five Forces Analysis
05. Geographical Segmentation
06. Key Leading Countries
07. Rate of Incidence and Prevalence
08. Vendor Landscape
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Hoffmann-La Roche Ltd.
15.2 GlaxoSmithKline plc
15.3 Merck & Co. Inc.
15.4 Gilead Sciences Inc.
15.5 Bristol-Myers Squibb Co.
16. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Hepatitis Drugs Market 2011-2015 (US$ billion)
Exhibit 2: Global Hepatitis Market by Category Segmentation
Exhibit 3: Global Hepatitis Drugs Market by Brand Segmentation 2011
Exhibit 4: Global Hepatitis Drugs Market by Geographical Segmentation 2011
Exhibit 5: Prevalence of Hepatitis B by Geographical Segmentation
Exhibit 6: Prevalence of Hepatitis B by Country Segmentation 2011-2015
Exhibit 7: Hepatitis C Infection by Source 2011
Exhibit 8: Global Hepatitis Drugs Market by Vendor Segmentation 2011
Exhibit 9: Global Hepatitis C Drugs Market by Vendor Segmentation 2011
To order this report:
Contact Nicolas: firstname.lastname@example.org
Intl: +1 805-652-2626
SOURCE ReportlinkerPR Newswire
Last updated on: 09/10/2012
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.